Type 2 diabetes is caused by insulin resistance coupled with an inability to produce enough
insulin to control blood glucose, and thiazolidinediones (TZDs) are the only current …

Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor
superfamily and they are essential regulators of cell differentiation, tissue development, and …

Adipocytes are the defining cell type of adipose tissue. Once considered a passive
participant in energy storage, adipose tissue is now recognized as a dynamic organ that …

Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated nuclear
receptor that regulates glucose and lipid metabolism, endothelial function and inflammation …

Highlights•Which molecular dynamics (MD) techniques are available for drug design?•How
is MD used to investigate ligand–macromolecule complexes?•How are MD studies applied …

PPARγ (peroxisome proliferator activated receptor γ) is a ligand activated transcription factor
of the nuclear receptor superfamily that controls the expression of a variety of genes …

A promising approach for treating type 2 diabetes mellitus (T2DM) is to target the
Peroxisome Proliferator-Activated Receptor γ (PPARγ) transcription factor, which regulates …

The thiazolidinediones (TZDs) are ligands of PPARγ that improve insulin sensitivity, but their
use is limited by significant side effects. Recently, we demonstrated a mechanism wherein …

In the current study, two series of novel thiazolidin-4-one benzenesulfonamide arylidene
hybrids 9a-l and 10a-f were designed, synthesized and tested in vitro for their PPARɣ …

Thiazolidinediones a class of drug, that provided a major breakthrough in the management
of type 2 diabetes since 1990. Following the discovery of PPARs, TZDs were the first class to …